TG Therapeutics, Inc. $TGTX Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 856.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 683,653 shares of the biopharmaceutical company’s stock after purchasing an additional 612,189 shares during the period. BNP Paribas Financial Markets owned 0.43% of TG Therapeutics worth $20,380,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of TGTX. Congress Asset Management Co. purchased a new stake in TG Therapeutics in the fourth quarter valued at $57,307,000. Man Group plc lifted its position in TG Therapeutics by 621.5% in the third quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock valued at $36,431,000 after acquiring an additional 868,697 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in TG Therapeutics by 21.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after acquiring an additional 345,059 shares during the last quarter. Vanguard Group Inc. lifted its position in TG Therapeutics by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock valued at $472,220,000 after acquiring an additional 319,703 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in TG Therapeutics by 45.0% in the third quarter. Two Sigma Investments LP now owns 889,870 shares of the biopharmaceutical company’s stock valued at $32,147,000 after acquiring an additional 276,163 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TGTX. Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Wall Street Zen cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of TG Therapeutics in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $52.50.

TG Therapeutics Stock Down 1.0%

TGTX stock opened at $40.16 on Friday. The company has a market cap of $6.15 billion, a P/E ratio of 14.04 and a beta of 1.68. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $44.65. The company’s 50-day moving average price is $37.05 and its 200 day moving average price is $32.59. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). The firm had revenue of $204.92 million for the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company’s quarterly revenue was up 69.5% compared to the same quarter last year. During the same period last year, the firm earned $0.03 EPS. On average, research analysts expect that TG Therapeutics, Inc. will post 1.51 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.